Cellectis Операционная прибыль

Что обозначает Операционная прибыль в Cellectis?

Операционная прибыль Cellectis является -487.66%

Какое определение для Операционная прибыль?



Показатель относительной доходности компании - это отношение операционной прибыли, деленной на чистую выручку и выраженной в процентах.

Operating margin is an indicator of profitability and is often used to compare the profitability of companies and industries of differing sizes. Companies are collections of projects and markets, individual areas can be judged on how successful they are at adding to the corporate net profit. Not all projects are of equal size, however, and one way to adjust for size is to divide the profit by sales revenue. The resulting ratio is the percentage of sales revenue that gets 'returned' to the company as net profits after all the related costs of the activity are deducted.

Операционная прибыль компаний в Health Care сектор на NASDAQ по сравнению с Cellectis

Что делает Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Компании с операционная прибыль похож на Cellectis